High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer

The development of new treatments for castrate resistant prostate cancer (CRPC) must address such challenges as intrinsic tumor heterogeneity and phenotypic plasticity. Combined PTEN/TP53 alterations represent a major genotype of CRPC (25–30%) and are associated with poor outcomes. Using tumor-deriv...

Descripción completa

Detalles Bibliográficos
Autores principales: Jansson, Keith H., Tucker, John B., Stahl, Lauren E., Simmons, John K., Fuller, Caitlyn, Beshiri, Michael L., Agarwal, Supreet, Fang, Lei, Hynes, Paul G., Alilin, Aian Neil, Lake, Ross, Abbey, Yasmine C., Cawley, Jacob, Tice, Caitlin M., Yin, JuanJuan, McKnight, Crystal, Klummp-Thomas, Carleen, Zhang, Xiaohu, Guha, Rajarshi, Hoover, Shelley, Simpson, R. Mark, Nguyen, Holly M., Corey, Eva, Thomas, Craig J., Proia, David A., Kelly, Kathleen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250716/
https://www.ncbi.nlm.nih.gov/pubmed/30467317
http://dx.doi.org/10.1038/s41598-018-35417-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6250716/
https://www.ncbi.nlm.nih.gov/pubmed/30467317
http://dx.doi.org/10.1038/s41598-018-35417-0

Ejemplares similares